US 12,485,172

Application 19/088,718 · Granted Dec 2, 2025

Pharmaceutical products and stable liquid compositions of il-17 antibodies

Estimated expiration

December 21, 2035

9y 32d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTIB2015059836: Resource not found (404)
Earliest effective filing
Dec 21, 2015
+ 20 years
Dec 21, 2035
PTA +0d
Dec 21, 2035
TD applied
Dec 21, 2035
Final
Dec 21, 2035

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
March 24, 2025
Earliest effective filing
December 21, 2015
Issue date
December 2, 2025
PTA
0 days
Base expiry (before PTA)
December 21, 2035

December 21, 2015 + 20 years = December 21, 2035

  • Continuation of application 18/481,213, filed Oct 4, 2023, issued as US 12,599,664
  • Divisional of application 15/538,257, filed Jun 21, 2017, issued as US 11,801,300
  • National stage entry of application PCTIB2015059836, filed Dec 21, 2015
  • National stage entry of application PCTIB2015059836, filed Dec 21, 2015
  • Divisional of application 15/538,257, filed Jun 21, 2017, issued as US 11,801,300
  • National stage entry of application PCTIB2015059836, filed Dec 21, 2015
  • PRO62/095,210 — Provisional — not used for base term
  • PRO62/095,210 — Provisional — not used for base term
  • PRO62/095,210 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 5 filed

TD caps expiration to December 21, 2035

  • US 12,485,172· Application 19/088,718(from application 19/088,718)Capping patent

    Pharmaceutical products and stable liquid compositions of il-17 antibodies

    Filing date
    Mar 24, 2025
    Earliest effective filing
    Dec 21, 2015
    Issue date
    Dec 2, 2025
    PTA
    0 days
    Calculated expiration
    Dec 21, 2035

    Continuation of 18/481,213, filed Oct 4, 2023, issued as US 12,599,664

    Divisional of 15/538,257, filed Jun 21, 2017, issued as US 11,801,300

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    Divisional of 15/538,257, filed Jun 21, 2017, issued as US 11,801,300

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    Dec 21, 2015 + 20y = Dec 21, 2035

  • US 12,599,664· Application 18/481,213(from application 18/481,213)

    Pharmaceutical products and stable liquid compositions of il-17 antibodies

    Filing date
    Oct 4, 2023
    Earliest effective filing
    Dec 21, 2015
    Issue date
    Apr 14, 2026
    PTA
    +12 days
    Calculated expiration
    Jan 2, 2036

    Divisional of 15/538,257, filed Jun 21, 2017, issued as US 11,801,300

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    Dec 21, 2015 + 20y + 12d PTA = Jan 2, 2036

  • US 12,485,173· Application 19/088,722(from application 19/088,722)

    Pharmaceutical products and stable liquid compositions of il-17 antibodies

    Filing date
    Mar 24, 2025
    Earliest effective filing
    Dec 21, 2015
    Issue date
    Dec 2, 2025
    PTA
    0 days
    Calculated expiration
    Dec 21, 2035

    Continuation of 18/481,213, filed Oct 4, 2023, issued as US 12,599,664

    Divisional of 15/538,257, filed Jun 21, 2017, issued as US 11,801,300

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    Divisional of 15/538,257, filed Jun 21, 2017, issued as US 11,801,300

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    Dec 21, 2015 + 20y = Dec 21, 2035

  • US 11,801,300· Application 15/538,257

    Pharmaceutical products and stable liquid compositions of il-17 antibodies

    Filing date
    Jun 21, 2017
    Earliest effective filing
    Dec 21, 2015
    Issue date
    Oct 31, 2023
    PTA
    0 days
    Calculated expiration
    Dec 21, 2035

    National stage entry of PCTIB2015059836, filed Dec 21, 2015

    Dec 21, 2015 + 20y = Dec 21, 2035

Notes (1)

  • [TD_DOCS_TRUNCATED] Found 5 filed TD documents; parsing first 3 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 19/088,718 · US 12,485,172

PatentReply compiles the prosecution history behind US 12,485,172: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12485172

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.